AML

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

AML
Mar 30, 2025, 13:55 | Science
Aaron Goodman: How I use maintenance therapy in AML
Aaron Goodman, Hematologist/Oncologist and an Associate Professor of Medicine at the University of California, shared…
Mar 14, 2025, 18:27 | Science
Frontline Therapy of AML in the Fit and Younger Population - Incorporating Molecularly Targeted Agents
A paper by Keith Pratz and Harry Erba was published in American Journal of Hematology,…
Mar 14, 2025, 14:58 | Science
Yan Leyfman: Advancing CAR Therapy for AML
Yan Leyfman, Co-founder and executive director of MedNews Week, shared an article by Sascha Haubner,…
Mar 12, 2025, 08:29 | Blog
Treosulfan with fludarabine approval - The Babak Lab
The Babak Lab shared a post on LinkedIn: "Clinical Mondays: Treosulfan with fludarabine approval. On…
Mar 4, 2025, 10:55 | Science
Talha Badar: Venetoclax and Decitabine vs Intensive Chemotherapy for Newly Diagnosed AML
Talha Badar, Hematology/Oncology specialist at Mayo Clinic, shared an article by Jing Lu, et al.…
Mar 4, 2025, 05:28 | Blog
Talha Badar: Clinical trials utilizing upfront venetoclax for AML
Talha Badar, Hematology/Oncology specialist at Mayo Clinic, shared a post on X: "Highlighting key data…
Mar 2, 2025, 08:51 | Blog
Joshua Zeidner: Magrolimab plus Azacitidine vs Physician Choice in Newly Diagnosed TP53-mut AML
Joshua Zeidner, Associate Professor at UNC Lineberger, shared on X about recent paper he and…
Feb 26, 2025, 10:02 | Insight
Hagop Kantarjian: Updated results of our frontline trial of FLAG-IDA+VEN
Hagop Kantarjian, Professor and Chair of the Department of Leukemia at The University of Texas…
Feb 25, 2025, 07:54 | Insight
Talha Badar: Bispecific and immune conjugates in the management of AML
Talha Badar, Hematology/Oncology specialist at Mayo Clinic, shared a thread on X: "Brief discussion on…
Feb 23, 2025, 10:22 | Blog
Tobias Neff: Mechanistic insight why stem-cell like leukemia has such poor outcomes
Tobias Neff, Executive Medical Director at Merck, shared an article by Fatemeh Alikarami, et al.…
Feb 19, 2025, 10:20 | Blog
Hagop Kantarjian: Impact of MRD clearance kinetics in patients with AML undergoing intensive chemotherapy
Hagop Kantarjian, Professor and Chair of the Department of Leukemia at The University of Texas…
Feb 7, 2025, 08:46 | Blog
Latest IACH Post ASH24 webinar dedicated to AML - IACH
IACH shared a post on X: "Now on demand! Our latest IACH Post ASH24 webinar…
Feb 7, 2025, 08:42 | Science
Shai Shimony: Biology and Management of NPM1 Mutated AML
Shai Shimony, Advanced Clinical Fellow at Dana-Farber Cancer Institute, shared an article by Evan C.…
Jan 24, 2025, 16:29 | Science
Alicia Perzolli: Excited to share our latest publication on PROTACs in pediatric acute myeloid leukemia
Alicia Perzolli, PhD Student at Princess Maxima Center, shared a post on LinkedIn about a…
Jan 15, 2025, 08:14 | Blog
Chokri Ben Lamine: Immune Targets in Hematologic Malignancies
Chokri Ben Lamine, Adult Hematology and stem cell transplantation Assistant Consultant at Oncology Center of…
Jan 10, 2025, 23:34 | Science
H. Moses Murdock: How I Treat AML relapse after allogeneic HCT
H. Moses Murdock, Hematology/Oncology fellow at Dana-Farber Cancer Institute, shared a post on X about…
Jan 4, 2025, 06:44 | Insight
Razan Mohty: Cellular therapies for acute leukemia - A Deep Dive from ASH24
Razan Mohty, Assistant Professor at UAB Medicine, shared a post on X: "Cellular therapies for…
Jan 2, 2025, 16:48 | Blog
Ahmed Kotb: FLT3 Inhibitors choice in AML
Ahmed Kotb, Hematologist and Bone marrow transplanter at King Faisal Specialist Hospital International Holding Company…
Jan 2, 2025, 16:41 | Blog
Ahmed Kotb: Triplet Regimens in AML - Promises and Challenges
Ahmed Kotb, Hematologist and Bone marrow transplanter at King Faisal Specialist Hospital International Holding Company…
Dec 30, 2024, 12:08 | Science
Nicholas Short: Measurable residual disease monitoring in AML
Nicholas Short, Associate Professor at the Department of Leukemia at MD Anderson Cancer Center, shared…
Dec 29, 2024, 12:36 | Blog
Hussein Abbas: DOD grant on TP53 AML was awarded
Hussein Abbas, Leukemia specialist at MD Anderson Cancer Center, posted on X: "DOD grant on…
Dec 26, 2024, 14:37 | Insight
Jayastu Senapati: Largest reported cohort in secondary AML
Jayastu Senapati, Assistant Professor of Leukemia at MD Anderson Cancer Center, shared on X: “Check…
Dec 24, 2024, 13:21 | Science
Total Body Irradiation vs Chemotherapy for Hematopoietic Stem Cell Transplant in Adult AML
Mostafa Faisal, Adjunct Assistant Professor at Alfaisal University, posted on X about recent paper by Hasaan…
Dec 22, 2024, 07:55 | Science
Ahmed Kotb: The Rapidly Evolving AML Treatment Landscape
Ahmed Kotb, Hematologist and Bone marrow transplanter at King Faisal Specialist Hospital International Holding Company…
Dec 21, 2024, 07:05 | Science
Naseema Gangat: Practical prognostic tool for the current standard of care in older/unfit AML
Naseema Gangat reshared a post by Vincent Rajkumar, Professor of Medicine at the Mayo Clinic…
Dec 19, 2024, 12:23 | Science
ASH: Triplet combination regimens demonstrate high response rates in multiple leukemias
Three clinical trials yield strong results with undetectable measurable residual disease and overall response rates…
Dec 13, 2024, 05:16 | Insight
MD Anderson Research Highlights: ASH 2024 Special Edition
Featuring novel treatments and research insights for MDS, leukemia, and lymphoma, encouraging long-term trial data,…
Dec 12, 2024, 16:38 | Insight
Yara Abdou: OlympiA, Updated analysis
Yara Abdou, Assistant Professor at the University of North Carolina, shared a post on X:…
Dec 11, 2024, 17:22 | Blog
Jessica M. Stempel on Aza-Ven +/- Pembro in older AML
Amer Zeidan, Associate Professor of Medicine at Yale University, shared a post on X: "Dr.…
Dec 11, 2024, 10:35 | Blog
Sam Yates on time to treatment in newly diagnosed AML - University of Chicago Leukemia Program
University of Chicago Leukemia Program shared a post on X: "A beautiful presentation by Sam…
Dec 5, 2024, 18:44 | Insight
Clinical perspectives on post-induction maintenance therapy in patients with AML
A recent paper by Kendra Sweet and Thomas Cluzeau was mentioned by Mohamed Benlazar, Professor of…
Dec 5, 2024, 16:20 | Insight
ASH24 studies from MD Anderson presented by Jayastu Senapati
Jayastu Senapati, Assistant Professor of Leukemia at MD Anderson Cancer Center, shared on X: “ASH24…
Dec 4, 2024, 09:54 | Positive
100 Influential Women in Oncology: Key Opinion Leaders to follow on Social Media in 2024
Starting on August 26, in honor of Women’s Equality Day in the United States, which…
Dec 2, 2024, 18:12 | Insight
Talha Badar: Excited to share my IIT just prior to ASH24
Talha Badar, Hematology/Oncology specialist in Mayo Clinic, shared a post on X: “Very excited to…
Nov 27, 2024, 18:52 | Insight
Aino-Maija Leppä: Exploring intra-tumor heterogeneity in complex karyotype AML
Aino-Maija Leppä, Postdoctoral Fellow at DKFZ German Cancer Research Center, shared on X: "Extremely proud…
Nov 20, 2024, 14:44 | Insight
Talha Badar: What we have learned about TP53-mutated AML?
Talha Badar, Hematology/Oncology specialist in Mayo Clinic, shared an article by Moazzam Shahzad on X:…
Nov 18, 2024, 13:05 | Blog
Kimberly Demirhan: Building Connections with Patient Advocates and Researchers at the JADPRO 2024
Kimberly Demirhan, Assistant director at ACCC, shared a post on LinkedIn: "One of the surprising…
Nov 15, 2024, 13:27 | Blog
Talha Badar: Management of AML in modern era at Pakistan Society of Hematology Annual Meeting
Talha Badar, Hematology/Oncology specialist in Mayo Clinic, shared a post on X: "It was a…
Nov 12, 2024, 08:27 | Insight
Decitabine, venetoclax and ponatinib for advanced phase CML and Philadelphia chromosome-positive AML
Benlazar S M A, Professor of hematology, Universitary hospital of Sidi Bel Abbés, shared an…
Nov 8, 2024, 14:30 | Insight
Keith W Pratz: The utility of post remission use of GCSF in the VIALE-A trial
Keith W Pratz, Director of Leukemia, Hospital of University of Pennsylvania Philadelphia, shared his recent…
Nov 7, 2024, 15:22 | Blog
Talha Badar: Prognostic impact of ‘multi-hit’ versus ‘single-hit’ TP53 alteration in patients with AML
Talha Badar posted on X about recent paper by him as first author, titled "Prognostic…
Nov 6, 2024, 16:47 | Insight
Curtis Lachowiez: Refining risk prediction for HMA and venetoclax-based treatment in AML
Curtis Lachowiez, Assistant Professor of Medicine at Oregon Health and Science University, shared a post…
Nov 6, 2024, 16:44 | Insight
Talha Badar: Post-transplant FLT3 maintenance therapy for AML
Talha Badar, Hematology/Oncology specialist in Mayo Clinic, shared a post on X: "For next few…
Nov 2, 2024, 17:34 | Insight
Venetoclax and Pegcrisantaspase for Relapsed or Refractory Acute Myeloid Leukemia
Anand Patel, Assistant Professor and Director of the Inpatient Leukemia Service at the University of…
Oct 28, 2024, 13:11 | Insight
Daniel Starczynowski: Uncovering a new mechanism behind chemotherapy resistance in AML
Daniel Starczynowski, Professor at Cincinnati Children's Hospital Medical Center, shared on LinkedIn: “We’re excited to…
Oct 26, 2024, 17:36 | Insight
Anand Patel: Prevention and Treatment of Transformation of MPNs to AML
Anand Patel, Assistant Professor and Director of the Inpatient Leukemia Service at the University of…
Oct 23, 2024, 14:21 | Blog
Oncology Brothers: The current treatment landscape/algorithm for AML
Mikkael A. Sekeres, Chief of Division Hematology at Sylvester Comprehensive Cancer Center, shared a post…
Oct 5, 2024, 11:39 | Insight
Talha Badar: Transplant or no transplant for TP53 mutated AML
Talha Badar shared a post on X about a recent paper titled "Transplant or no…
Oct 1, 2024, 17:45 | Insight
Talha Badar: Different aspects of TP53 mutated AML
Talha Badar shared a post on X: "I will share our collaborative effort in looking at…
Oct 1, 2024, 15:57 | Insight
Measurable residual disease monitoring in AML
Top Biomedical Science shared on X: “Measurable residual disease monitoring in AML: Prospects for therapeutic…
Sep 27, 2024, 12:38 | Blog
Mikkael A. Sekeres: Great science, even better camaraderie
Mikkael A. Sekeres, Chief of Division Hematology at Sylvester Comprehensive Cancer Center, shared a post…
Sep 24, 2024, 22:44 | Blog
How does COVID-19 impact patients with AML? - Cancer Nursing Today
Mamtha Balla, Transplant Oncology-ID fellow, MD Anderson Cancer Center, shared a post by Cancer Nursing…
Sep 17, 2024, 16:25 | Blog
Sanam Loghavi: Menin inhibitors in AML—exciting development and combination therapies
Sanam Loghavi posted the following on X: “Menin inhibitors are the most exciting class of…
Sep 14, 2024, 17:48 | Insight
May Daher: A novel NK immune evasion strategy in AML
May Daher shared a post on X: "Excited to share our manuscript published in Science…
Sep 11, 2024, 09:16 | Insight
Naveen Pemmaraju: Pivekimab sunirine in relapsed or refractory acute myeloid leukaemia
Naveen Pemmaraju shared a post on X about a recent paper by Naval Daver et…
Sep 6, 2024, 16:18 | Blog
Nishant Rajendra Tiwari: Common microscopy and flow cytometry patterns for acute leukemias
Nishant Rajendra Tiwari, Hemato-oncology fellow at OU Health Stephenson Cancer Center, shared a thread on…
Sep 2, 2024, 16:02 | Blog
Naveen Pemmaraju: Fantastic venue with mix of pre-clinical and clinical presentations focused on novel pathways in heme malignancies
Naveen Pemmaraju shared on LinkedIn: “I recently gave an invited faculty talk at ISEH -…
Aug 29, 2024, 20:11 | Career
Alique Topalian received the Inspirational Award from the Armenian Bone Marrow Donor Registry
Alique Topalian shared a post by University of Cincinnati Cancer Center, on LinkedIn adding: “So…
Aug 29, 2024, 17:16 | Blog
Day in the Life of a Leukaemia PhD researcher - Manchester Cancer Research Centre
Manchester Cancer Research Centre shared a post on LinkedIn: "Day in the Life of a…
Aug 29, 2024, 16:59 | Insight
Talha Badar: Overview of AML induction strategies
Talha Badar shared a post on X: "Overview of AML induction strategies! AML eligible for…
Aug 27, 2024, 23:03 | Blog
Jan-Henning Klusmann: Thrilled to be part of the newly published 'Acute Myeloid Leukemia in Children'
Jan-Henning Klusmann, Pediatric hematologist and oncologist at Goethe University Frankfurt, shared on X: "Thrilled to…
Aug 24, 2024, 10:51 | Insight
Shahrin Ahmed: High health care utilization and poor survival rate in older adults with AML
Shahrin Ahmed, Medical Specialist at the Canadian Cancer Society, shared a post on X: “Older…
Aug 22, 2024, 13:46 | Insight
Hagop Kantarjian: The latest advancements and progress in treating AML
Hagop Kantarjian shared a post on X: “Recording now available: The latest advancements and progress…
Aug 19, 2024, 10:29 | Insight
New ELN classification of AML receiving less intense therapies
Eddie Cliff, Haematology Registrar at Peter MacCallum Cancer Centre, shared a post on X about…
Aug 19, 2024, 10:07 | Insight
Nicolas Duployez: A 4-gene prognostic model stratified OS outcomes with VEN-AZA treatment in AML
Nicolas Duployez, Molecular Biologist at Lille University Hospital, shared on X about a recent paper…
Aug 17, 2024, 07:45 | Insight
Razan Mohty: Outcomes of patients with IDH1 or 2 mutated AML after alloHCT
Razan Mohty, Assistant Professor at UAB Medicine, shared a post on X about a recent…
Aug 16, 2024, 14:19 | Insight
Talha Badar: Key takeaways from molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML
Talha Badar shared a post on X: “Molecular, clinical, and therapeutic determinants of outcome in…
Aug 14, 2024, 07:20 | Drugs
Keith W Pratz: Novel risk signature for AML treated with Azacitidine and Venetoclax
Keith W Pratz, Director of Leukemia at the Hospital of University of Pennsylvania, shared on…
Aug 13, 2024, 14:03 | Societies
Should all FMS-like (FLT3)-positive AML receive maintenance therapy post-allograft? - COSTEM Congress
COSTEM Congress shared on X: "We're looking forward to hearing from Andreas Burchert and Arnon…
Aug 13, 2024, 13:50 | Insight
Fieke Hoff: The need for a refined risk stratification model for older patients with AML
Fieke Hoff, Clinical hematology/oncology fellow at NIH NHLBI, shared on X: "Excited to share our…
Aug 12, 2024, 20:58 | Insight
Post-transplant maintenance for AML: Review of literature by Talha Badar
Talha Badar shared a post on X: "Post transplant maintenance for AML. How should you…
Aug 10, 2024, 01:18 | Blog
JAMA Oncology Review: The Latest Treatment Options for Acute Myeloid Leukemia by Sylvester Comprehensive Cancer Center
Recently approved drugs are rapidly changing the treatment of patients with acute myeloid leukemia (AML),…
Aug 5, 2024, 16:32 | Societies
Joint IACH-IACRLRD webinar on Targeted diagnosis and therapy of NPM1-mutated AML
The International Academy for Clinical Hematology (IACH) shared on X: "Our latest Joint IACH-IACRLRD webinar:…
Aug 4, 2024, 07:01 | Insight
Rama Al Hamed: Allogeneic SCT in de novo core-binding factor AML in first complete remission
Rama Al Hamed, Hematology/Oncology Fellow at Herbert Irving Comprehensive Cancer Centre, shared on X: "Allogeneic…
Aug 4, 2024, 06:30 | Insight
Lisa Bouchier-Hayes: Caspase-2 in nucleophosmin-mutated acute myeloid leukemia
Lisa Bouchier-Hayes, Associate Professor at Baylor College of Medicine, shared on X: "So excited to…
Aug 1, 2024, 02:29 | Blog
Early Intervention Key to Managing Shwachman-Diamond Syndrome: Insights from Dana-Farber's Molecular Tumor Board
Dana-Farber Cancer Institute shared a post on LinkedIn: "Imagine trying to navigate a paper map…
Jul 20, 2024, 14:27 | Insight
Naveen Pemmaraju: Important paper on AML and Hyperleukocytosis
Naveen Pemmaraju shared a post about a paper titled "Outcomes of Patients With Newly Diagnosed…
Jul 19, 2024, 13:27 | Insight
Fadi Haddad: Hyperleukocytosis in Acute myeloid leukemia
Fadi Haddad, Assistant Professor at Leukemia Department at MD Anderson Cancer Center, shared a post…
Jul 19, 2024, 13:19 | Insight
Sanam Loghavi: Optical genome mapping in acute myeloid leukemia
Sanam Loghavi, shared a post on X about a recent paper titled "Optical genome mapping improves…
Jul 15, 2024, 12:11 | Insight
Finishing the MMPCC series for 2023-24 with Joe Maakaron
Alain Mina, Assistant research physician of Immune Deficiency Cellular Therapy Program at NIH-NCI, shared on…
Jul 15, 2024, 06:09 | Insight
Naveen Pemmaraju: Superb talk on developing immune-targeting agents in AML
Naveen Pemmaraju shared on X: "Absolutely superb talk by Dr Yasmin Abaza at AML-ALL US…
Jul 13, 2024, 19:41 | Insight
Joshua Zeidner: Subset analyses from QUAZAR study
Joshua Zeidner, Associate Professor at UNC Lineberger, shared on X about a recent paper by…
Jul 12, 2024, 16:59 | Insight
Naveen Pemmaraju: Two of the finest people I have ever known
Naveen Pemmaraju shared a post on X: “Just landed MD Education AML-ALL US Focus meeting…
Jul 9, 2024, 00:57 | Insight
Talha Badar: Outcome after stopping venetoclax and azacitidine
Talha Badar shared on X: “American Journal of Hematology, Blood Research Journal, Wiley Online Library.…
Jul 8, 2024, 16:34 | Insight
Aref Al-Kali: AML is hanging with use of FLT3i and Allo BMT
Aref Al-Kali, Hematologist/Oncologist at Mayo Clinic, shared on X: "Outcome of t6;9 AML changing with…
Jul 6, 2024, 11:09 | Insight
Therapeutic time window from diagnosis to treatment for elderly AML patients
Matteo Molica, Hematologist Medical Director at UOC Hematology Oncohaematology Department at the Apulian Ciaccio Hospital,…
Jun 28, 2024, 14:06 | Blog
Vincent Rajkumar: Cure is a simple word. But there is confusion when it comes to cancer
Vincent Rajkumar shared a post on X: “Cure is a simple word. But there is…
Jun 24, 2024, 13:16 | Insight
Hagop Kantarjian: NPM1-mutant myeloid neoplasms should be treated with AML-type treatment
Hagop Kantarjian shared on X:                . "NPM1-mutant myeloid…
Jun 21, 2024, 12:25 | Blog
Sanam Loghavi: Another day in the life of a hematopathologist
Sanam Loghavi shared on X/Twitter: "Another day in the life of a hematopathologist….. To say I…
Jun 21, 2024, 05:21 | Blog
Mikkael A. Sekeres: The circle of academic hematology life
Mikkael A. Sekeres, Chief of the Division of Hematology at Sylvester Comprehensive Cancer Center, shared…
Jun 18, 2024, 23:17 | Insight
Talha Badar: TP53 mutation in Myeloproliferative neoplasms
Talha Badar shared on X:      , "Genomic landscape, impact allelic burden, time to…
Jun 18, 2024, 23:01 | Insight
Dr. Naval Daver presented results of ENHANCE-3 study at EHA2024
Talha Badar shared on X:         . "Dr. Naval Daver: Presented results of…
Jun 18, 2024, 14:51 | Insight
Amer Zeidan: Our newest paper on 61 TP53-mutated AML
Amer Zeidan shared on X: "Our newest paper with a detailed Integrated analysis of genetic,…
Jun 18, 2024, 11:23 | Blog
Wafik S. El-Deiry: Informative presentation by John Reagan about “MyeloMATCH"
Wafik S. El-Deiry shared on LinkedIn:               . "Very informative…
Jun 11, 2024, 14:59 | Insight
Timos Papagatsias: EHA24 is expected to be one of the most exciting EHA conferences to-date!
Timos Papagatsias, CEO of LucidQuest shared a post on LinkedIn: “EHA24 is fast approaching and…
May 22, 2024, 04:26 | Blog
Warren Fingrut: 2nd-ever Health Disparities in Hematologic Malignancies Conference
Warren Fingrut, Hematologist and Stem Cell Transplant physician at MD Anderson Cancer Center, posted on…
May 19, 2024, 09:37 | Blog
Eline Bertrums on International collaborations and Genetic Insights in Childhood Cancer
Eline Bertrums, Physician assistant (ANIOS) pediatrics at Gelderland Valley Hospital, shared a post on LinkedIn:…
May 14, 2024, 15:10 | Blog
Naval Daver shares updates on novel emerging therapies in AML - MD Anderson Cancer Center
MD Anderson Cancer Center shared on X: “There’s much more optimism and hope that we…
May 14, 2024, 10:12 | Blog
Aaron Goodman: CD markers simplified!
Quoting Aaron Goodman on X: “CD markers simplified! CD34+ = Blast CD3+ = T-cell CD19+ = B-cell…
May 13, 2024, 13:11 | Insight
Justin Kaner: To transplant or not to transplant….. 
Justin Kaner, Assistant Professor  of the Leukemia Program at Weill Cornell, shared on X: "To…
12
All: 143 Posts: 1 - 100
Special Coverage